Related references
Note: Only part of the references are listed.Therapeutic vaccines for breast cancer: Has the time finally come?
Chiara Corti et al.
EUROPEAN JOURNAL OF CANCER (2022)
HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases
Geetha Shanmugam et al.
TRANSLATIONAL ONCOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Immune activation and evolution through chemotherapy plus checkpoint blockade in triple-negative breast cancer
Siang-Boon Koh et al.
CANCER CELL (2021)
Parity and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis
Chenyang Li et al.
CANCER EPIDEMIOLOGY (2021)
Cancer Vaccines, Treatment of the Future: With Emphasis on HER2-Positive Breast Cancer
Sandeep Pallerla et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer A Phase 3 Randomized Clinical Trial
Hope S. Rugo et al.
JAMA ONCOLOGY (2021)
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
S. Dent et al.
ANNALS OF ONCOLOGY (2021)
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Laura Cortesi et al.
TARGETED ONCOLOGY (2021)
Immunomodulating Therapies in Breast Cancer-From Prognosis to Clinical Practice
Marcus Schmidt et al.
CANCERS (2021)
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study
Hope S. Rugo et al.
LANCET ONCOLOGY (2021)
Effectiveness of Alpelisib plus Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer
Stuart Turner et al.
ONCOLOGIST (2021)
A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.
Tao Sun et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More
Yang Li et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
Ilana Schlam et al.
NPJ BREAST CANCER (2021)
Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
Emanuela Ferraro et al.
BREAST CANCER RESEARCH (2021)
Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib
Lara Ulrich et al.
BREAST CANCER-TARGETS AND THERAPY (2021)
Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers
Komal Jhaveri et al.
CLINICAL CANCER RESEARCH (2021)
Breast cancer vaccines: Heeding the lessons of the past to guide a path forward
Cinzia Solinas et al.
CANCER TREATMENT REVIEWS (2020)
Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials
Jing Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
The application and prospect of CDK4/6 inhibitors in malignant solid tumors
Qi Du et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
Anthony Goncalves et al.
CANCERS (2020)
Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer
Mafalda Oliveira et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2020)
Future perspectives and challenges with CDK4/6 inhibitors in hormone receptor-positive metastatic breast cancer
Soley Bayraktar et al.
FUTURE ONCOLOGY (2020)
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Maddison Rose et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)
Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond
Ricardo L. B. Costa et al.
NPJ BREAST CANCER (2020)
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer
Ana C. Garrido-Castro et al.
BREAST CANCER RESEARCH (2020)
PI3K inhibitors: review and new strategies
Mingzhen Zhang et al.
CHEMICAL SCIENCE (2020)
The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Takashi Nakada et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Hyun Tae Lee et al.
MOLECULES (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System
Colette Moses et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women
Robert J. Cersosimo
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2019)
Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives
Luisa Carbognin et al.
CANCERS (2019)
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)
Jame Abraham et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
Silvia Paola Corona et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2018)
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
Patrick Schoffski et al.
BREAST CANCER RESEARCH (2018)
Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety
Ferdinando Riccardi et al.
MOLECULAR AND CLINICAL ONCOLOGY (2018)
The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Ami N. Shah et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment
Shengnan Yu et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2017)
Neoadjuvant Therapy for HER2-positive Breast Cancer
Rachel Wuerstlein et al.
REVIEWS ON RECENT CLINICAL TRIALS (2017)
Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: From laboratory to patients
Filip Janku
CANCER TREATMENT REVIEWS (2017)
Olaparib
Sebastiaan C. Goulooze et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation
A-S Tigan et al.
ONCOGENE (2016)
LKB1/AMPK inhibits TGF-β1 production and the TGF-β signaling pathway in breast cancer cells
Nian-Shuang Li et al.
TUMOR BIOLOGY (2016)
Pertuzumab and trastuzumab: the rationale way to synergy
Sandrine Richard et al.
ANAIS DA ACADEMIA BRASILEIRA DE CIENCIAS (2016)
The therapeutic potential of mTOR inhibitors in breast cancer
Linda S. Steelman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
The development and use of the E75 (HER2 369-377) peptide vaccine
Guy T. Clifton et al.
FUTURE ONCOLOGY (2016)
Treating cancer with selective CDK4/6 inhibitors
Ben O'Leary et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Bergapten drives autophagy through the up-regulation of PTEN expression in breast cancer cells
Francesca De Amicis et al.
MOLECULAR CANCER (2015)
Role of the LKB1/AMPK pathway in tumor invasion and metastasis of cancer cells (Review)
Nianshuang Li et al.
ONCOLOGY REPORTS (2015)
Everolimus in the Treatment of Metastatic Breast Cancer
Melanie E. Royce et al.
BREAST CANCER-BASIC AND CLINICAL RESEARCH (2015)
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Elisavet Paplomata et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer
Francis Arena
CANCER MANAGEMENT AND RESEARCH (2014)
Targeted therapy for HER2 positive breast cancer
Jason A. Incorvati et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Phase II trial of temsirolimus in patients with metastatic breast cancer
Gini F. Fleming et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Impact of Breast Cancer Subtypes and Treatment on Survival: An Analysis Spanning Two Decades
Reina Haque et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
Honokiol: A Novel Natural Agent for Cancer Prevention and Therapy
S. Arora et al.
CURRENT MOLECULAR MEDICINE (2012)
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis
Arumugam Nagalingam et al.
BREAST CANCER RESEARCH (2012)
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Virginia E. Kwitkowski et al.
ONCOLOGIST (2010)
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
Henry L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2
Qin Ryan et al.
ONCOLOGIST (2008)
Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
Lisa A. Carey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
S Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy
F Chang et al.
LEUKEMIA (2003)
Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death
Z Herceg et al.
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2001)
Share Paper
